Distribution agreement signed with Cambridge Life Sciences Ltd, regarding the UK market

Hemcheck Sweden AB has signed an exclusive distribution agreement with Cambridge Life Sciences Ltd (“CLS”), a leading manufacturer and distributor of assays, laboratory and medical equipment in the UK. The agreement will be in force immediately and valid for three years, concerning the UK market.

– CLS is a well-established distributor in the UK with both its own manufacturing and reference laboratory in addition to its distribution of well-known products. We look forward to starting the collaboration, says Joen Averstad, CEO of Hemcheck.

– Hemcheck has a unique solution for a well-known problem which fits well into our product portfolio. The products have excellent potential in the UK and we look forward to a successful partnership with Hemcheck, says Peter Blake, Director of CLS.

For further information contact:

Hemcheck Sweden AB (publ)

Joen Averstad, CEO

Tel: +46 76 108 8191

Email: joen.averstad@hemcheck.com

About CLS

CLS was established in 1981 and has a broad range of in-vitro diagnostic products in its portfolio. It is part of the Pharmed Group and has its own reference laboratory. Its a UK based manufacturing and distribution company that develops, manufactures and distributes products and services. The main product areas are autoimmune disease, infectious disease, therapeutic drug monitoring, clinical chemistry and near patient testing products. CLS has direct access to the UK Secondary Care Market through its own dedicated sales team and to the UK Primary Care Market through Hillside Medical Supplies also part of the Pharmed Group

Read more at http://www.clsdiagnostics.com/ and https://www.hillsidemedical.co.uk

About Hemcheck

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.